BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

Trading 08-28 13:38:10 EDT

366.26

-6.23

-1.67%

High372.00	Low364.75	Vol61.97K
Open369.13	D1 Closing372.49	Amplitude1.95%
Mkt Cap41.75B	Tradable Cap31.39B	Total Shares114.00M
T/O22.72M	T/O Rate0.07%	Tradable Shares85.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":366.255,"timestamp":1787938653338,"preClose":372.49,"halted":0,"volume":61970,"delay":0,"changeRate":-0.01673870439474889,"floatShares":85693500,"shares":113999999,"eps":5.589356,"marketStatus":"Trading","change":-6.235,"latestTime":"08-28 13:38:10 EDT","open":369.13,"high":372,"low":364.75,"amount":22718516.1879,"amplitude":0.019464,"askPrice":366.62,"askSize":59,"bidPrice":365.71,"bidSize":80,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787947200000},"marketStatusCode":2,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":372.49,"preHourTrading":{"tag":"盘前","latestPrice":368.01,"preClose":372.49,"latestTime":"09:29 EDT","volume":113,"amount":42233.23585,"timestamp":1787923741049,"change":-4.48,"changeRate":-0.012027,"amplitude":0.018792},"postHourTrading":{"tag":"盘后","latestPrice":372.49,"preClose":372.49,"latestTime":"19:38 EDT","volume":12807,"amount":4770467.2,"timestamp":1787873910583,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.359133,"impliedVol":0.3221,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/ONC/tweets","defaultTab":"tweets","newsList":[{"id":"1141434847","title":"Beone Medicines' First-Half Profit Surges 386% as Core Drug Drives Revenue Past $3.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141434847","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141434847?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:44","pubTimestamp":1787741086,"startTime":"0","endTime":"0","summary":"Beone Medicines has delivered a stellar first-half performance for fiscal 2026, with profitability climbing sharply year-on-year and validating the effectiveness of its commercial strategy.According...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU1969619763.USD","BK1588","KURE","LU1303224171.USD","BK4585","LU2328871848.SGD","06160","688235","BK1583","BK1500","LU0588546209.SGD","ONC","LU0307460666.USD","LU0828237510.HKD","BK4588","LU0228659784.USD","BK4526","BK4139","LU1770034418.SGD","BK1161","LU1251922891.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107537379","title":"BEONE MEDICINES Reports Strong First-Half Profit Surge of 385.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107537379","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107537379?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:16","pubTimestamp":1787739404,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) has unveiled its interim results for the six months ended June 30, 2026, posting a net profit of $464 million, a substantial year-on-year increase of 385.8%.The company's...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","BK4588","BK1500","LU0588546209.SGD","ONC","LU1969619763.USD","LU1251922891.USD","BK1588","BK1161","LU1303224171.USD","BK4585","KURE","LU0228659784.USD","BK0239","BK1583","BK4526","06160","BK4139","688235","LU0828237510.HKD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175580","title":"BeOne Medicines' Tacabrutideg Presents 'Sizable Opportunity' in CSU, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175580","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175580?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:12","pubTimestamp":1787670744,"startTime":"0","endTime":"0","summary":"BeOne Medicines'  BTK degrader tacabrutideg presents a \"sizable opportunity\" in chronic spontaneous urticaria or CSU, RBC Capital Markets said in a Tuesday note.CSU is an inflammatory skin condition that can be a major market with peak sales estimates of about $3 billion, the brokerage said. BTK degraders have the potential to top BTK inhibitors in CSU, likely exceeding inhibitors in terms of potency and effect durability, RBC noted.Nurix Therapeutics  has reported that its BTK degrader bexobrutideg demonstrated greater potency in CSU compared with Novartis'  BTK inhibitor remibrutinib, and RBC sees tacabrutideg's overall efficacy profile as \"broadly comparable\" with bexobrutideg, according to the note.BeOne Medicines is planning to advance tacabrutideg to phase 2 studies in CSU, RBC noted.RBC has an outperform rating and $450 price target on BeOne Medicines.Price: 376.42, Change: +4.44, Percent Change: +1.19","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0320765489.SGD","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","LU0211331839.USD","IE0002141913.USD","MDCO","ONC","BK4007","BK4532","BK4139","IE00BJJMRZ35.SGD","BK4526","IE00B2B36J28.USD","BK4578","IE00BFTCPJ56.SGD","MEDX","PPH","NRIX","LU0070302665.USD","NVS","IE0009355771.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","FRTY","PINK","BBP","BK4588","IBB","TBXU","ONC","IDNA","LFSC","TECB","SYNB","RSPH","IEIH","IYH","GNMX","BK4526","BMED","NVIB","XLVX","BK4139","LABU","MEDI","GDOC","PSCH","BK4585","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662273574","title":"Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Biogen (BIIB) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662273574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662273574?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:40","pubTimestamp":1787654408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GE Healthcare Technologies Inc (GEHC), Biogen (BIIB)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ge-healthcare-technologies-inc-gehc-biogen-biib-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ge-healthcare-technologies-inc-gehc-biogen-biib-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1551013342.USD","LGHT","LU0689472784.USD","LU0077335932.USD","LU2756315664.SGD","MISL","PPA","LU2168564222.USD","LU0354030438.USD","IE00B894F039.SGD","BK4187","LU0354030511.USD","GEHC","LABU","XLV","LU0943347566.SGD","UXI","BK4543","EXI","LU1366192091.USD","LU1988902786.USD","LU2168564065.EUR","PBE","DFEN","MDCO","LU0868494617.USD","BK4581","XAR","BIIB","ITA","BK4526","LU0109394709.USD","LU1280957306.USD","LU1551013425.SGD","NATO","LU2264538146.SGD","LU0889565916.HKD","LU1066051498.USD","GE","BK4082","BK4588","XBI","BMED","IE00B19Z9P08.USD","BK4139","LU0353189763.USD","LU2543165471.USD","ONC","LU0689626769.HKD","TRUI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660980444","title":"BeOne Medicines (ONC), What Is Behind The Fresh Attention Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660980444","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660980444?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:24","pubTimestamp":1787127890,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month.\nSee our latest analysis for BeOne Medicines.\nFollowing the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","BK4585","BK4526","MDCO","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469996","title":"BeOne Medicines, Foundations Renew Deal to Deliver Cancer Medicine to Poor Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469996","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660469996?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:27","pubTimestamp":1787048858,"startTime":"0","endTime":"0","summary":"BeOne Medicines , the BeOne Care Foundation, and The Max Foundation have renewed their partnership through 2028 to expand access to Brukinsa for the treatment of chronic lymphocytic leukemia in low- and middle-income countries, the organizations said Tuesday.The program is planned to support around 1,000 patients, they said.The program has given access to the drug to 300 patients in Armenia, Ethiopia, and Nepal, they said.The partnership combines Max Foundation's expertise in overseeing oncology access programs with donated Brukinsa and includes a $1 million grant from the BeOne Care Foundation, the organizations said.Shares of the company were up 1.2% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK4139","BK4585","BK4526","BK4588","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123461158","title":"Beone Medicines Rises 1.34% With H1 Revenue Reaching 22.2 Billion Yuan as Global Expansion Accelerates","url":"https://stock-news.laohu8.com/highlight/detail?id=1123461158","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123461158?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:11","pubTimestamp":1787047890,"startTime":"0","endTime":"0","summary":"Beone Medicines closed at 293.78 yuan today, up 1.34%, with a trading volume of 1.736 billion yuan, a turnover rate of 5.147%, and a volume ratio of 0.71. The company's total market capitalization...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1770034418.SGD","LU0828237510.HKD","LU1969619763.USD","BK4526","BK4585","LU1303224171.USD","LU1719994722.HKD","LU0307460666.USD","BK1583","06160","LU0228659784.USD","ONC","688235","BK0239","BK1500","BK1588","LU2328871848.SGD","LU0588546209.SGD","BK4588","BK4139","LU1251922891.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660652469","title":"BeOne Medicines renews partnerships to expand access to Brukinsa in leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2660652469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660652469?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:10","pubTimestamp":1787047854,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC), together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a global health nonprofi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-renews-partnerships-to-expand-access-to-brukinsa-in-leukemia-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-renews-partnerships-to-expand-access-to-brukinsa-in-leukemia-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4588","MDCO","ONC","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659178401","title":"BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2659178401","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659178401?lang=en_us&edition=fundamental","pubTime":"2026-08-15 17:25","pubTimestamp":1786785946,"startTime":"0","endTime":"0","summary":"BeOne Medicines (NasdaqGS: ONC) announces a multi-part collaboration with Revolution Medicines focused on oncology RAS(ON) inhibitors.\nThe agreement gives BeOne access to four advanced-stage RAS(ON) inhibitors and includes joint clinical studies for combination cancer therapies.\nBeOne secures exclusive development and commercialization rights for these RAS(ON) assets in select Asian markets.\n\nThis type of oncology partnership highlights how drug developers and healthcare technology companies...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-secures-rights-to-four-rason-inhibitors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861219969.SGD","LU2360107325.USD","LU1548497426.USD","LU1720051108.HKD","BK4526","LU2298322129.HKD","LU1854103824.USD","MDCO","BK4512","LU1854104046.USD","LU1861214812.USD","BK4141","LU2357305700.SGD","LU0724618433.USD","IE00BD6J9T35.USD","IE00BFMHRM44.USD","BK4139","BK4585","LU1978683503.SGD","LU1720051017.SGD","BK4605","ONC","BK4588","LU1983260115.SGD","IE00BZ199S13.USD","LU0348723411.USD","LU1861215975.USD","ON","LU1861220033.SGD","LU0124384867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110314526","title":"JPMorgan Chase & Co. Increases Stake in BEONE MEDICINES by Over 4.1 Million Shares at Approximately HKD 219.79 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1110314526","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110314526?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:51","pubTimestamp":1786708275,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on August 11, JPMorgan Chase & Co. increased its holdings in BEONE MEDICINES (06160) by 4,119,720 shares.The transaction was executed at an average...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JPM","LU0320765489.SGD","LU0149725797.USD","BK1588","BK4533","LU2237443895.HKD","FTXO","LU1969619763.USD","LU2264538146.SGD","IE00BJTD4N35.SGD","LU2242649171.HKD","IE0034235188.USD","SG9999002232.USD","LU0070302665.USD","LU0640476718.USD","JPMLL","LU1988902786.USD","BK4582","LU2237443382.USD","BK4585","BK1500","LU0234572021.USD","LU1668664300.SGD","BK4550","LU0170899867.USD","LU2552382132.HKD","IE0034235295.USD","LU2552382215.SGD","LU0267386448.USD","LU1770034418.SGD","LU0868494617.USD","IYF","LU0048584097.USD","XLF","FNCL","IE00BK4W5M84.HKD","LU1551013342.USD","LU2746668461.USD","IE0034235303.USD","LU1116320901.HKD","LU0323591593.USD","LU0187121727.USD","LU0345769631.USD","LU2106854487.HKD","IE00BDRTCR15.USD","LU2357305700.SGD","LU2430703178.SGD","LU0256863902.USD","LU1363072403.SGD","LU1244550494.USD","IE00BBT3K403.USD","VFH","IXG","LU2756315664.SGD","UYG","TFNS","LU0496365809.HKD","KBWB","BK4207","LU1244550577.SGD","LU0882574139.USD","LU1119994496.HKD","IE00BLSP4239.USD","LU1551013425.SGD","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0820562030.AUD","IE00BJLML261.HKD","LU0859254822.USD","IE00BK4W5L77.USD","LU0417517546.SGD","688235","IE00B775SV38.USD","LU1032466523.USD","LU1548497426.USD","LU0211331839.USD","LU0208291251.USD","IE000M9KFDE8.USD","BK4588","JPMO","LU0203347892.USD","LU1974910355.USD","LU1894683348.USD","LU2244417387.USD","LU0345769128.USD","LU2328871848.SGD","LU2456880835.USD","BK4526","LU0689472784.USD","IE00B3S45H60.SGD","LU0211326755.USD","LU0964807845.USD","LU2211815571.USD","LU2746668974.SGD","LU0256863811.USD","LU0265550359.USD","LU1670628061.USD","LU1914381329.SGD","LU2505996509.AUD","BK4566","LU2357627491.SGD","LU0215105999.USD","LU1251922891.USD","LU1496350502.SGD","IE00BKVL7J92.USD","LU1894683264.USD","LU2430703251.USD","LU1145028129.USD","LU0211326839.USD","LU1720051017.SGD","LU2417539215.USD","LU0942090050.USD","LU0310799852.SGD","LU0787776722.HKD","LU1064131342.USD","LU2237443978.SGD","LU0106261372.USD","LU1670627923.USD","BK4581","IE00BLSP4452.SGD","LU2237443622.USD","IE00BHPRN162.USD","IE00B1XK9C88.USD","LU0820561818.USD","LU0971096721.USD","06160","LU1629891620.HKD","BK4534","LU1084165304.USD","LU0943347566.SGD","LU1303224171.USD","LU2592432038.USD","IE00BWXC8680.SGD","IE00BZ1G4Q59.USD","LU1720051108.HKD","IE00BN8TJ469.HKD","LU0211328371.USD","LU0234570918.USD","LU1280957306.USD","LU2023250504.SGD","LU0251132253.USD","LU2213496289.HKD","BK0239","JPX","LU0588546209.SGD","LU1719994722.HKD","LU1496350171.SGD","LU1244550221.USD","BK4516","LU2430703095.HKD","LU2381873111.SGD","LU2756315318.SGD","LU1267930490.SGD","LU2236285917.USD","ONC","LU0320765646.SGD","PGF","EWH","LU0211327993.USD","LU2237443465.HKD","LU1917777945.USD","LU2023250330.USD","IYG","LU2023250843.SGD","LU0307460666.USD","LU0345770993.USD","LU0203345920.USD","TRUF","IE00BFXG1179.USD","KURE","LU0828237510.HKD","LU0345770308.USD","LU0683600562.USD","IE00BJTD4V19.USD","LU2505996681.GBP","LU0976567544.SGD","LU2054465674.USD","IE00BKDWB100.SGD","BK4139","LU0228659784.USD","LU1261432733.SGD","LU0868494708.USD","LU2552382058.USD","LU1366192091.USD","LU2462157665.USD","LU0006306889.USD","BK1583","IE00BYXW3230.USD","LU0238689110.USD","BK1161","LU0106831901.USD","LU2237443549.SGD","BK4504","IE00BDCRKT87.USD","JPO","LU1116320737.USD","LU1162221912.USD","LU0265550946.USD","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166703578","title":"Beone Medicines Awards Over 40,000 Restricted Stock Units to Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=1166703578","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166703578?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:58","pubTimestamp":1786611511,"startTime":"0","endTime":"0","summary":"Beone Medicines Ltd (06160) has announced a new equity incentive grant. On August 7, 2026, the Compensation Committee of the Board approved the award of 40,764 restricted stock units (RSUs)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","KURE","BK4526","BK0239","LU0228659784.USD","BK1588","LU2328871848.SGD","BK4588","LU1251922891.USD","LU0307460666.USD","06160","LU1969619763.USD","LU0588546209.SGD","688235","LU0828237510.HKD","LU1770034418.SGD","BK1583","BK1161","ONC","BK4139","LU1719994722.HKD","LU1303224171.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160122906","title":"Pharmaceutical Rally Continues: Gan&Lee Pharmaceuticals Hits Limit-Up, Beone Medicines Logs 6-Day Winning Streak; Huabao Funds' HK Medical and Innovation Drug ETFs Rise for Third Consecutive Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1160122906","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160122906?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447849,"startTime":"0","endTime":"0","summary":"On August 11, A-shares and Hong Kong stocks experienced a significant pullback, with healthcare assets broadly peaking and then retreating due to overall market conditions. However, the innovative...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1251922891.USD","603087","BK4139","LU0828237510.HKD","LU1770034418.SGD","BK0239","LU1303224171.USD","LU0588546209.SGD","FLHK","LU1969619763.USD","159828","LU2328871848.SGD","LU0228659784.USD","KURE","ONC","BK1588","BK4526","BK4585","BK1500","LU0307460666.USD","06160","LU1719994722.HKD","BK1583","159316","BK1161","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969501","title":"Beone Medicines : Jefferies Raises Target Price to $395 from $388","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658969501?lang=en_us&edition=fundamental","pubTime":"2026-08-11 11:43","pubTimestamp":1786419836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4471I1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","ONC","BK0239","688235","BK4585","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171969636","title":"CICC Retains Outperform Rating on BeiGene (06160) with HKD 266 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1171969636","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171969636?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:50","pubTimestamp":1786413022,"startTime":"0","endTime":"0","summary":"CICC has released a research report stating that it maintains its earnings forecasts for BeiGene (06160) for 2026 and 2027. The firm retains an Outperform industry rating and, based on a DCF model,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU0588546209.SGD","LU1969619763.USD","LU0228659784.USD","BK1161","BK1500","KURE","BK1588","688235","BK4585","BK1583","LU1770034418.SGD","EWH","BK4588","LU1303224171.USD","BK4526","LU0307460666.USD","LU1719994722.HKD","BK0239","ONC","LU0828237510.HKD","BK4139","LU2328871848.SGD","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123475942","title":"BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1123475942","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123475942?lang=en_us&edition=fundamental","pubTime":"2026-08-11 09:46","pubTimestamp":1786412777,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) saw its shares surge more than 4% during early trading hours, before settling at a 2.72% gain to 219 Hong Kong dollars, with a trading volume of 297 million Hong Kong...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","IE00BJJMRZ35.SGD","VXUS","06160","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1303224171.USD","IE0009355771.USD","KURE","KCAI","BBH","688235","LU0828237510.HKD","LU1770034418.SGD","BK1161","LU0320765992.SGD","LU1969619763.USD","LU1719994722.HKD","BK1588","BK4526","CANC","LU0109394709.USD","IE00B4R5TH58.HKD","PTH","BK1500","IE0009354923.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IDNA","BK1583","BK4585","BK4588","LU0588546209.SGD","LU0228659784.USD","LU2328871848.SGD","ONC","BK4139","IE0002141913.USD","LU0307460666.USD","BK0239","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658110987","title":"BeOne Medicines partners with Revolution Medicines for clinical development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658110987","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658110987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:15","pubTimestamp":1786356922,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-partners-with-revolution-medicines-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-partners-with-revolution-medicines-for-clinical-development-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","IE0009355771.USD","BBH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IDNA","BK4588","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","ONC","LU0109394709.USD","BK4526","IE00B2B36J28.USD","CANC","LU0320765992.SGD","BK4585","RVMD","PTH","IE0002141913.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175410099","title":"BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1175410099","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175410099?lang=en_us&edition=fundamental","pubTime":"2026-08-10 11:08","pubTimestamp":1786331293,"startTime":"0","endTime":"0","summary":"BOCOM International has released a research report raising its price target for BEONE MEDICINES (06160) from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.In the second quarter, Zanubutinib...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","EWH","LU1303224171.USD","LU0228659784.USD","LU1719994722.HKD","BK1161","BK4585","LU1251922891.USD","688235","LU0588546209.SGD","LU0307460666.USD","BK0239","BK1583","ONC","06160","LU0828237510.HKD","LU2328871848.SGD","BK1500","BK1588","BK4588","BK4139","BK4526","KURE","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101035030","title":"Goldman Sachs Competitor Adjusts BeOne Medicines Target Upward, Bullish Ratings Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1101035030","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101035030?lang=en_us&edition=fundamental","pubTime":"2026-08-09 09:50","pubTimestamp":1786240220,"startTime":"0","endTime":"0","summary":"A financial research report from a major investment bank indicates that, considering the strong growth of BeOne Medicines (stock code: 06160) drug sales and improved cost control, its net profit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","BK1500","KURE","688235","BK4526","LU2328871848.SGD","BK0239","BK4588","LU0307460666.USD","BK1583","BK1161","LU0828237510.HKD","06160","LU1770034418.SGD","LU1969619763.USD","LU1303224171.USD","EWH","LU0228659784.USD","LU1719994722.HKD","BK4139","BK4585","LU1251922891.USD","LU0588546209.SGD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154033718","title":"BEONE MEDICINES Confirms External CMO Supply for Baiyueda, All Processes On Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=1154033718","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154033718?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:21","pubTimestamp":1786112491,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES stated during a research survey that its product, Baiyueda, is currently being supplied by an external Contract Manufacturing Organization (CMO). All related processes are proceeding...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","BK4585","BK1500","BK1588","BK0239","06160","LU0307460666.USD","BK1583","ONC","LU0588546209.SGD","LU1770034418.SGD","BK4139","BK1161","LU1251922891.USD","LU2328871848.SGD","BK4526","688235","KURE","LU1719994722.HKD","LU1969619763.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":0.1272},{"period":"3month","weight":0.2937},{"period":"6month","weight":0.1751},{"period":"1year","weight":0.2411},{"period":"ytd","weight":0.2261}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0408},{"period":"3month","weight":0.0193},{"period":"6month","weight":0.1241},{"period":"1year","weight":0.1925},{"period":"ytd","weight":0.1308}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.083709},{"month":2,"riseRate":0.6,"avgChangeRate":0.027535},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.02929},{"month":4,"riseRate":0.363636,"avgChangeRate":0.018832},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.019621},{"month":6,"riseRate":0.454545,"avgChangeRate":0.010403},{"month":7,"riseRate":0.818182,"avgChangeRate":0.143728},{"month":8,"riseRate":0.636364,"avgChangeRate":0.047339},{"month":9,"riseRate":0.6,"avgChangeRate":0.069537},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004517},{"month":11,"riseRate":0.6,"avgChangeRate":0.063715},{"month":12,"riseRate":0.3,"avgChangeRate":-0.043663}],"exchange":"NASDAQ","name":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","nameEN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","securityTypeName":"DR","adrRate":"1:13"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS,ONC,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票老虎国际,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票行情,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股价,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股市,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票价格,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票交易,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票购买,BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction